跳至主要内容
临床试验/CTRI/2023/11/059490
CTRI/2023/11/059490尚未招募Unknown

A prospective efficacy & safety study of intravenous Ferric Carboxy Maltose in breast cancer patients with iron deficiency anemia - FCM study

Emcure Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Females 18 yrs or older
  • 2. Histologically proven diagnosis of breast cancer patients on follow-up, rather than on ongoing chemotherapy.
  • 3. Haemoglobin 8-10g/dl or transferrin saturation =20% regardless of the haemoglobin level.

排除标准

  • 1. Patients with other obvious known causes of anaemia like blood loss,
  • Megaloblastic anaemia, Pernicious anaemia, and Haemolytic anaemia
  • 2. Patients who are a known case of uncontrolled hypertension, recent acute
  • illness, hematologic disorders, or those receiving any other experimental drug
  • 3. Patients with a known significant dysfunction of pulmonary, cardiovascular,
  • endocrine, neurological, gastrointestinal, or genito-urinary systems not
  • attributable to underlying malignancy
  • 4. Patients who are receiving Iron supplements in oral or parenteral forms
  • 5. Patients who are on erythropoietin stimulating agents

研究者

相似试验